 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Kite Pharma, Inc. (KITE) focuses on the development and commercialization of novel cancer immunotherapy products.
The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 2 clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma, including primary mediastinal B cell lymphoma and transformed follicular lymphoma.
The company is also conducting a Phase 2 clinical trial of KTE-C19 on patients with relapsed/refractory mantle cell lymphoma; a Phase 1-2 clinical trial of KTE-C19 on adult patients with relapsed/refractory acute lymphoblastic leukemia; and a Phase 1-2 clinical trial of KTE-C19 in pediatric patients with relapsed/refractory. In addition, it engages in developing T cell receptors-based therapies, which targets self-antigens, viral antigens, and neo-antigens.
The company has a research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; collaboration agreements with the Surgery Branch of the National Cancer Institute and bluebird bio, Inc.; cooperative research and development agreements with the U.S. Department of Health and Human Services; a license agreement with Cabaret Biotech Ltd.; a license and research agreement with Alpine Immune Sciences, Inc.; and a clinical trial collaboration agreement with Genentech to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab in patients with non-Hodgkin lymphoma.
Shares have formed a bullish "cup and handle" and higher share prices are expected for this stock.
52-Weeks Trading Range: $38.41 - $87.50
Entry Point: $53.00
Stop Loss: $49.40
Target Price: $58.30
KITE closed at $47.50
